Cziperle David J
Thoracic Surgery, Ann B. Barshinger Cancer Institute, Lancaster, PA, USA.
Med Devices (Auckl). 2021 Jun 1;14:155-163. doi: 10.2147/MDER.S298207. eCollection 2021.
Adequate hemostasis during surgical procedures is essential for successful patient outcomes and reduced healthcare resource utilization. Topical hemostatic agents can act as catalysts for the clotting cascade or as a scaffold to promote platelet activation or aggregation. Although an ever-increasing number of topical absorbable hemostatic agents are now available for perioperative use, health care providers are disadvantaged by the lack of comparative data on feasibility, clinical effectiveness, advantages, and limitations of each in specific surgical settings. This knowledge is important for appropriate product choice when patient characteristics, type of surgical procedure, type of bleeding, and product availability may differ widely. This manuscript provides the first comprehensive overview of Avitene™ Microfibrillar Collagen Hemostat (MCH), a bovine collagen-based absorbable hemostat that has been widely used for over four decades in the United States and abroad. MCH is indicated as an adjunct to hemostasis across a broad spectrum of surgical specialties and has been shown to achieve hemostasis with positive patient outcomes and a favorable safety profile in many applications, including hepatic, orthopedic, splenic, oral, and otolaryngologic surgery. Although published clinical data regarding the use of MCH in cardiovascular surgery is limited, evidence suggests moderate use in this specialty. The information contained in this systematic review will help health care providers understand the clinical use and effectiveness of the product to determine appropriate use in differing bleeding scenarios across multiple surgical specialties. Future studies may include comparative functional and cost analyses to explore the economic advantages of using absorbable hemostatic agents compared with each other or with conventional techniques of hemostasis, when appropriate.
手术过程中充分止血对于患者获得成功治疗结果以及减少医疗资源利用至关重要。局部止血剂可作为凝血级联反应的催化剂,或作为促进血小板活化或聚集的支架。尽管目前有越来越多的局部可吸收止血剂可用于围手术期,但医疗服务提供者因缺乏关于每种止血剂在特定手术环境中的可行性、临床有效性、优势和局限性的比较数据而处于劣势。当患者特征、手术类型、出血类型和产品可用性可能差异很大时,这些知识对于正确选择产品很重要。本手稿首次全面概述了Avitene™微纤维胶原止血剂(MCH),这是一种基于牛胶原蛋白的可吸收止血剂,在美国和国外已广泛使用了四十多年。MCH被指定为广泛手术专科止血的辅助药物,并且在许多应用中,包括肝脏、骨科、脾脏、口腔和耳鼻喉科手术,已显示出能实现止血并带来良好的患者治疗结果和良好的安全性。尽管关于MCH在心血管手术中使用的已发表临床数据有限,但有证据表明在该专科中可适度使用。本系统评价中包含的信息将帮助医疗服务提供者了解该产品的临床用途和有效性,以确定在多个手术专科不同出血情况下的适当使用方法。未来的研究可能包括比较功能和成本分析,以探讨在适当情况下使用可吸收止血剂相对于彼此或与传统止血技术相比的经济优势。